130 related articles for article (PubMed ID: 38554799)
21. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma.
Tripathi RC; Li J; Tripathi BJ; Chalam KV; Adamis AP
Ophthalmology; 1998 Feb; 105(2):232-7. PubMed ID: 9479280
[TBL] [Abstract][Full Text] [Related]
22. Aflibercept for the treatment of neovascular glaucoma.
SooHoo JR; Seibold LK; Pantcheva MB; Kahook MY
Clin Exp Ophthalmol; 2015 Dec; 43(9):803-7. PubMed ID: 26016631
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of periostin and tenascin-C in eyes with neovascular glaucoma secondary to PDR.
Ishikawa K; Kohno RI; Mori K; Murakami Y; Nakao S; Akiyama M; Yoshida S; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):621-628. PubMed ID: 31863397
[TBL] [Abstract][Full Text] [Related]
24. Short Communication: Increase of Sialylated N-Glycansin Eyes with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy.
Inafuku S; Noda K; Amano M; Nishimura S; Ishida S
Curr Eye Res; 2016 May; 41(5):721-4. PubMed ID: 26177396
[TBL] [Abstract][Full Text] [Related]
25. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.
Sun Y; Liang Y; Zhou P; Wu H; Hou X; Ren Z; Li X; Zhao M
BMC Ophthalmol; 2016 Aug; 16(1):150. PubMed ID: 27576739
[TBL] [Abstract][Full Text] [Related]
26. Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.
Tatsumi T; Yamamoto S; Uehara J; Sugawara T; Baba T; Inoue M; Hata H; Mitamura Y
Graefes Arch Clin Exp Ophthalmol; 2013 May; 251(5):1355-60. PubMed ID: 23250484
[TBL] [Abstract][Full Text] [Related]
27. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy.
Wakabayashi Y; Usui Y; Okunuki Y; Ueda S; Kimura K; Muramatsu D; Kezuka T; Goto H
Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6403-10. PubMed ID: 22899753
[TBL] [Abstract][Full Text] [Related]
28. Differences in aqueous humor protein profiles in patients with proliferative diabetic retinopathy before and after conbercept treatment.
Wang T; Chen H; Du X; Li N; Chen Y; Min H
J Proteomics; 2023 Mar; 276():104838. PubMed ID: 36764651
[TBL] [Abstract][Full Text] [Related]
29. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients.
Sugimoto Y; Mochizuki H; Okumichi H; Takumida M; Takamatsu M; Kawamata S; Kiuchi Y
Graefes Arch Clin Exp Ophthalmol; 2010 Nov; 248(11):1601-9. PubMed ID: 20524132
[TBL] [Abstract][Full Text] [Related]
30. [Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma].
Kozawa T; Sone H; Okuda Y; Kawakami Y; Sekine Y; Imai M; Hommura S; Inatomi M; Yaguchi S; Matsuo K; Segawa T; Suzuki H; Yamashita K
Nippon Ganka Gakkai Zasshi; 1998 Nov; 102(11):731-8. PubMed ID: 9852717
[TBL] [Abstract][Full Text] [Related]
31. [The change of the level of the vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma before and after anterior retinal cryotherapy].
Chen T; Zeng SQ; Lu YY; Huang LY; Dai H
Zhonghua Yan Ke Za Zhi; 2007 Jul; 43(7):622-5. PubMed ID: 17897552
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma.
Hasanreisoglu M; Weinberger D; Mimouni K; Luski M; Bourla D; Kramer M; Robinson A; Axer-Siegel R
Eur J Ophthalmol; 2009; 19(4):607-12. PubMed ID: 19551676
[TBL] [Abstract][Full Text] [Related]
33. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
34. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.
Falavarjani KG; Modarres M; Nazari H
Eye (Lond); 2010 Apr; 24(4):717-9. PubMed ID: 19407842
[TBL] [Abstract][Full Text] [Related]
35. Anti-vascular endothelial growth factor for neovascular glaucoma.
Simha A; Aziz K; Braganza A; Abraham L; Samuel P; Lindsley KB
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD007920. PubMed ID: 32027392
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
37. Elevated soluble vascular endothelial growth factor receptor levels in aqueous humor from patients with different types of glaucoma.
Nakamura K; Kojima S; Inoue-Mochita M; Tanihara H; Inoue T
Exp Eye Res; 2022 Oct; 223():109204. PubMed ID: 35921964
[TBL] [Abstract][Full Text] [Related]
38. RISK FACTORS FOR SURGERY OR BLINDNESS IN NEOVASCULAR GLAUCOMA EYES TREATED WITH ANTI-VEGF INJECTIONS BY A RETINA SPECIALIST.
Massenzio E; Xu D; Abishek R; Wibbelsman TD; Sheng Y; Obeid A; Bhatt S; Zhang Q; Sharpe J; Park CH; Spirn MJ; Gupta OP; Chiang A; Shukla A; Shalaby WS; Myers JS; Hsu J
Retina; 2023 Jul; 43(7):1150-1159. PubMed ID: 36913629
[TBL] [Abstract][Full Text] [Related]
39. Quantitative analysis of metabolites in glucose metabolism in the aqueous humor of patients with central retinal vein occlusion.
Wei P; He M; Teng H; Han G
Exp Eye Res; 2020 Feb; 191():107919. PubMed ID: 31923416
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.
Olmos LC; Sayed MS; Moraczewski AL; Gedde SJ; Rosenfeld PJ; Shi W; Feuer WJ; Lee RK
Eye (Lond); 2016 Mar; 30(3):463-72. PubMed ID: 26681145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
